Form 4: Perrigo Executive Ronald Janish Granted 9,748 Restricted Stock Units

Perrigo Company plc's EVP of Global Operations and Supply Chain, Ronald Craig Janish, was granted 9,748 Restricted Stock Units, aligning executive incentives with shareholder value.

Summary

• Ronald Craig Janish, Executive Vice President, Global Operations & Supply Chain & Chief Technology Officer of Perrigo Company plc (PRGO), reported changes in beneficial ownership.
• On June 6, 2025, Mr. Janish acquired 9,748 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one Perrigo Company plc ordinary share.
• These RSUs will vest in three equal annual installments, with the first vesting date on June 6, 2026.
• Following this transaction, Mr. Janish beneficially owns 35,558 Ordinary Shares directly and 9,748 Restricted Stock Units directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as the grant of equity to a key executive aligns their interests with shareholders, promoting long-term value creation. This is a standard and expected compensation event.

Positives

• The grant of Restricted Stock Units to a key executive like Ronald Craig Janish aligns his long-term interests with those of the shareholders, incentivizing performance and retention.
• Equity-based compensation is a standard practice that can motivate management to enhance company value.

Future Outlook

The acquired Restricted Stock Units are set to vest in three equal annual installments, commencing on June 6, 2026, indicating a long-term incentive structure for the executive.

Industry Context

The grant of Restricted Stock Units to a senior executive is a common and widely accepted practice in corporate compensation across various industries, designed to retain talent and align management incentives with shareholder returns. This filing reflects a routine aspect of executive compensation within the pharmaceutical and consumer healthcare sector.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice across global industries, including the pharmaceutical and consumer healthcare sectors, comparable to companies like Johnson & Johnson, Pfizer, or Procter & Gamble, which frequently utilize equity grants to incentivize their leadership.
• The vesting schedule of three equal annual installments is typical for long-term incentive plans, aiming to foster sustained performance and executive retention over several years.

Stakeholder Impact

• Shareholders: The equity grant aligns the executive's financial interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: May signal stability in leadership and a commitment to long-term incentives for key personnel.

Next Steps

• Vesting of the 9,748 Restricted Stock Units in three equal annual installments, beginning June 6, 2026.

Key Dates

Keywords

Perrigo, PRGO, SEC Form 4, Insider Trading, Executive Compensation, Restricted Stock Units, Equity Grant, Beneficial Ownership